|1.||Ribas, Antoni: 12 articles (01/2015 - 01/2010)|
|2.||Bollag, Gideon: 8 articles (01/2015 - 01/2010)|
|3.||Flaherty, Keith T: 5 articles (03/2012 - 08/2010)|
|4.||Lee, Richard J: 5 articles (02/2012 - 08/2010)|
|5.||Lo, Roger S: 5 articles (08/2011 - 01/2010)|
|6.||Koya, Richard C: 4 articles (01/2015 - 01/2010)|
|7.||McArthur, Grant A: 4 articles (10/2014 - 08/2010)|
|8.||Herlyn, Meenhard: 4 articles (07/2013 - 10/2010)|
|9.||Sosman, Jeffrey A: 4 articles (02/2012 - 08/2010)|
|10.||Chmielowski, Bartosz: 4 articles (02/2012 - 01/2010)|
|1.||Melanoma (Melanoma, Malignant)
03/01/2012 - "Inhibition of the BRAF(V600E) oncoprotein by the small-molecule drug PLX4032 (vemurafenib) is highly effective in the treatment of melanoma. "
01/01/2011 - "Nevertheless, even PLX4032 monotherapy should be viewed as a significant improvement of the current state-of-the-art treatment of malignant melanoma."
07/01/2011 - "Vemurafenib (PLX4032) and GSK2118436, two orally available and well tolerated agents are on the verge of transforming the landscape of melanoma therapy based on the promising results of their respective phase I, II, and III trials."
01/01/2011 - "However, the outstanding results on melanoma survival observed with novel selective inhibitors of B-RAF, such as PLX4032 give hope that melanoma can be cured. "
08/01/2010 - "We sought to investigate the efficacy of PLX4032 (BRAF inhibitor) to identify patterns/predictors of response/resistance and to study the effects of BRAF in melanoma. "
01/01/2015 - "Furthermore, TILs isolated from SM1 tumors treated with PLX3397 and PLX4032 displayed higher immune potentiating activity. "
12/01/2012 - "However, the average duration of response was 6-7 months before tumor regrowth, indicating the acquisition of resistance to PLX4032. "
01/01/2012 - "Early clinical results with the BRAF-selective inhibitors PLX4032 and GSK2118436 suggest that this strategy will prove successful in a select group of patients whose tumors are driven by oncogenic BRAF."
03/01/2011 - "This review article will address: (a) preclinical data on the antitumor activity of BRAF inhibitors in cell lines/ in vivo models and their opposing functions as inhibitors or activators of the MAPK pathway, depending on the cellular context; (b) drug development from non-selective RAF inhibitors to selective BRAF inhibitors, such as PLX4032 and GSK2118436, with emphasis in the clinical efficacy and toxicity of these agents; and (c) possible mechanisms of resistance to BRAF inhibitors and strategies to overcome its development in BRAF mutant tumors."
11/01/2010 - "PLX4032, a selective and potent inhibitor of BRAF V600E mutant tumor cells, has shown inhibition of tumor growth in cell lines harboring BRAF V600E mutations. "
|3.||Thyroid Neoplasms (Thyroid Cancer)
01/01/2014 - "PLX4032 has potent anti-proliferative effects selectively in BRAF-mutated thyroid cancer cells. "
01/28/2011 - "Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cells sensitivity to PLX4032 and demonstrated its specific potential as an effective and BRAF(T1799A) mutation-selective therapeutic agent for thyroid cancer."
06/01/2013 - "When BRAF(V600E)-positive thyroid cancer cells were incubated with the specific BRAF inhibitor PLX4032, sensitivity to gefitinib was restored. "
01/01/2010 - "We examined the activity of PLX4032 and PLX4720 in thyroid carcinoma cell lines harboring BRAF V600E (8505C, BCPAP, SW1736, BHT101), NRAS Q61R (HTH7), KRAS G12R (CAL62), HRAS G13R (C643), or RET/PTC1 (TPC-1) oncogenes. "
07/01/2014 - "To investigate this, we used mass spectrometry to complete a global phosphoproteomic analysis of a BRAFV600E thyroid cancer cell line (SW1736) after treatment with the mutation-selective inhibitor vemurafenib (PLX4032) and MEK1/2 inhibitor selumetinib (AZD6244). "
|4.||Sarcoma (Soft Tissue Sarcoma)
|1.||Small Interfering RNA (siRNA)
|2.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|3.||Calcibiotic Root Canal Sealer
|8.||Adenosine Triphosphate (ATP)
|1.||Heterologous Transplantation (Xenotransplantation)